Giredestrant plus everolimus reduced the risk of progression or death by 44% in the ITT population and 62% in ESR1-mutated disease in phase 3 evERA data published in NEJM.
|Videos|March 15, 2019
Advanced Ovarian Cancer
Advanced Ovarian Cancer
Advertisement
Case: A 54-Year-Old Woman Diagnosed With Advanced Ovarian Cancer
H & P
- A 54-year-old woman presents after referral from her gynecologist for widespread tenderness, abdominal discomfort, and urinary symptoms. Pelvic exam performed by the gynecologist revealed a suspicious mass on her right ovary.
- Postmenopausal with two children
- PE: reveals an obese woman (BMI = 31 kg/m2) with mild hypertension and pre-diabetes; abdomen shows dullness to percussion
- BP = 130/85 mm Hg
- Fasting glucose = 115 mg/dL
- Waist: hip ratio = 0.90
Imaging
- CT with contrast of the pelvis, abdomen, and chest reveals widespread peritoneal lesions and abdominal lymph node involvement
- Malignant ascites present
Biopsy and labs:
- Pathology, high-grade serous adenocarcinoma, ovarian primary
- BRCA1/2 status: negative
- CA-125: 785 U/mL
Treatment
- She underwent hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and tumor debulking; residual disease after cytoreduction = 1.1 cm
- Diagnosis, stage IIIC ovarian cancer, grade 3
- Started on every-3-week carboplatin and paclitaxel IV plus bevacizumab every 3 weeks
Advertisement
Related to this article
The oral azacitidine/cedazuridine combination was compared with subcutaneous azacitidine in the phase 3 portion of the AZTOUND trial.
Adding zabilugene almadenorepvec to standard gemcitabine/nab-paclitaxel extends survival and response in newly diagnosed metastatic pancreatic cancer, with manageable safety signals.
Late 2026 FDA oncology rulings may reshape care—from CSF-1R and ALK drugs to oral SERDs and BCMA CAR T breakthroughs.
Resubmitted FDA filing advances off-the-shelf EBV-specific T-cell therapy tab-cel for relapsed EBV+ PTLD after transplant, with longer follow-up.
Resection with cesium-131 tile-based radiation therapy prolonged time to surgical bed recurrence vs resection with stereotactic radiation in the phase 3 ROADS trial.
Degevma was approved for skeletal-related events in adults with bone metastases, giant cell tumor of bone, and the treatment of hypercalcemia of malignancy.
FDA fast-tracks plinabulin plus docetaxel for post-immunotherapy non-squamous NSCLC, as DUBLIN-4 phase 3 targets survival gains.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Denosumab Biosimilar Approved For Existing Oncology Indications
2
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
3
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
4
Tile-Based Radiation Improves Local Control in Resected Brain Metastases
5